WI Company Recalls Eczema Cream After Contamination Found

WISCONSIN — A Wisconsin company is recalling an eczema cream sold nationwide through Amazon and other distributors after the product was found to be contaminated with Staphylococcus aureus, according to the U.S. Food and Drug Administration.

Pharmacal, based in Jackson, Wisconsin, recalled one lot of MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream, a 6-ounce topical cream used for eczema-related skin irritation and rash.

The FDA published the recall Tuesday, May 12. The company announced the recall May 8.

Consumers who have the recalled cream should stop using it and throw it away

No adverse events related to the recall had been reported as of the company’s announcement, according to Pharmacal.

The recalled product is:

• MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream
• 6-ounce tube
• Product code: 5106
• UPC: 012277051067
• Lot: 1024088
• Expiration date: November 2026

The lot number can be found on the crimped end of the tube.

The cream was distributed nationwide to wholesale, retail and internet distributors, including Amazon, according to the FDA.

The announcement also listed H-E-B Grocery as a retail distributor.

The company said using the contaminated cream could result in infections ranging from localized infections to severe or life-threatening adverse events.

People with weakened immune systems or compromised skin, including those with wounds, burns or skin disorders, are at higher risk for serious infections, according to the recall notice.

Possible serious infections include:

• Skin and skin structure infections
• Infective endocarditis, an infection of the heart valves
• Bone and joint infections
• Bloodstream infections
• Sepsis
• Septic shock

Consumers with questions can contact Pharmacal at 800-558-6614 or aimho@pharmacalway.com from 8 a.m. to 5 p.m. Central time Monday through Friday.

Anyone who experienced problems that may be related to using the cream should contact a physician or health care provider. Adverse reactions or quality problems can also be reported to the FDA’s MedWatch Adverse Event Reporting program.